APA (7th ed.) Citation

JJ, C., LP, G., SD, R., & DL, V. (2009). The Potential Clinical and Economic Outcomes of Pharmacogenomic Approaches to EGFR-Tyrosine Kinase Inhibitor Therapy in Non-Small-Cell Lung Cancer. Value in Health, 12(1), 20. https://doi.org/10.1111/j.1524-4733.2008.00415.x

Chicago Style (17th ed.) Citation

JJ, Carlson, Garrison LP, Ramsey SD, and Veenstra DL. "The Potential Clinical and Economic Outcomes of Pharmacogenomic Approaches to EGFR-Tyrosine Kinase Inhibitor Therapy in Non-Small-Cell Lung Cancer." Value in Health 12, no. 1 (2009): 20. https://doi.org/10.1111/j.1524-4733.2008.00415.x.

MLA (9th ed.) Citation

JJ, Carlson, et al. "The Potential Clinical and Economic Outcomes of Pharmacogenomic Approaches to EGFR-Tyrosine Kinase Inhibitor Therapy in Non-Small-Cell Lung Cancer." Value in Health, vol. 12, no. 1, 2009, p. 20, https://doi.org/10.1111/j.1524-4733.2008.00415.x.